Tag: lyra stock
-
LYRA Stock Soars: Phase 3 Trial Success for LYR-210 CRS Treatment
New Phase 3 data reveals significant CRS symptom improvement with LYR-210. Key endpoints met with p=0.0078. Potential FDA submission path emerging. See full results for LYRA stock.